A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Unsatisfactory Symptom State (ESSPRI Score ≥ 5) | Azienda Ospedaliero - Universitaria SS. Antonio e Biagio e Cesare Arrigo - Alessandria

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Unsatisfactory Symptom State (ESSPRI Score ≥ 5)

Promotore: Horizon Therapeutics Ireland DAC

Acronimo: HZNP-DAZ-303

Struttura: Reumatologia

Sperimentatore principale: Stobbione Paolo

Stato arruolamento: In attesa di arruolamento